193 related articles for article (PubMed ID: 30253076)
1. Diffuse alveolar hemorrhage with pseudoprogression during nivolumab therapy in a patient with malignant melanoma.
Ikeda T; Yamaguchi H; Dotsu Y; Taniguchi H; Gyoutoku H; Senju H; Sakamoto N; Iwanaga S; Kuwatsuka Y; Fukuda M; Mukae H
Thorac Cancer; 2018 Nov; 9(11):1522-1524. PubMed ID: 30253076
[TBL] [Abstract][Full Text] [Related]
2. Intralesional interleukin-2 for unresectable mucosal melanoma refractory to nivolumab.
Heppt MV; Goldscheider I; Tietze JK; Berking C
Cancer Immunol Immunother; 2017 Oct; 66(10):1377-1378. PubMed ID: 28497158
[No Abstract] [Full Text] [Related]
3. A Rare Case of Diffuse Alveolar Hemorrhage Caused by Fentanyl Inhalation.
Nangrani A; Chung J; Jyang E; Nangrani K; Schmidt M
Cureus; 2023 Oct; 15(10):e47598. PubMed ID: 38022247
[TBL] [Abstract][Full Text] [Related]
4. Pseudoprogression in a patient with metastatic melanoma treated with PD-1 and LAG-3 inhibition.
Wu LW; Tao JJ; McDonnell D; Izar B
Melanoma Res; 2024 Apr; ():. PubMed ID: 38640504
[TBL] [Abstract][Full Text] [Related]
5. Severe complications of nivolumab monotherapy in an adolescent with malignant melanoma.
Grzegorczyk A; Marczyńska Z; Matkowski R; Ziętek M; Pietras W; Latos-Grażyńska E; Kałwak K; Dachowska-Kałwak I
Cent Eur J Immunol; 2023; 48(3):251-256. PubMed ID: 37901868
[TBL] [Abstract][Full Text] [Related]
6. From apparent pseudoprogression to durable complete remission of expansile destructive sinonasal mucosal melanoma under pembrolizumab after primary endoscopic resection: A case report.
Lu HC; Shen PH; Kok VC
SAGE Open Med Case Rep; 2024; 12():2050313X241253471. PubMed ID: 38741602
[TBL] [Abstract][Full Text] [Related]
7. Amplification and attenuation of lung metastases depending on glucocorticoid dosage implicating long-acting activated memory cells induced by nivolumab against malignant melanoma.
Katagiri K; Shiga K; Saito D; Oikawa SI; Ikeda A; Tsuchida K; Miyaguchi J
Clin Case Rep; 2019 Sep; 7(9):1709-1713. PubMed ID: 31534732
[TBL] [Abstract][Full Text] [Related]
8. Lung brain metastasis pseudoprogression after nivolumab and ipilimumab combination treatment.
Melian M; Lorente D; Aparici F; Juan O
Thorac Cancer; 2018 Dec; 9(12):1770-1773. PubMed ID: 30276979
[TBL] [Abstract][Full Text] [Related]
9. Change in the lymphocyte-to-monocyte ratio is an early surrogate marker of the efficacy of nivolumab monotherapy in advanced non-small-cell lung cancer.
Sekine K; Kanda S; Goto Y; Horinouchi H; Fujiwara Y; Yamamoto N; Motoi N; Ohe Y
Lung Cancer; 2018 Oct; 124():179-188. PubMed ID: 30268458
[TBL] [Abstract][Full Text] [Related]
10. Immune Microenvironment Differences Between Squamous and Non-squamous Non-small-cell Lung Cancer and Their Influence on the Prognosis.
Meng X; Gao Y; Yang L; Jing H; Teng F; Huang Z; Xing L
Clin Lung Cancer; 2019 Jan; 20(1):48-58. PubMed ID: 30341017
[TBL] [Abstract][Full Text] [Related]
11. Serum concentrations of HGF are correlated with response to anti-PD-1 antibody therapy in patients with metastatic melanoma.
Kubo Y; Fukushima S; Inamori Y; Tsuruta M; Egashira S; Yamada-Kanazawa S; Nakahara S; Tokuzumi A; Miyashita A; Aoi J; Kajihara I; Tomita Y; Wakamatsu K; Jinnin M; Ihn H
J Dermatol Sci; 2019 Jan; 93(1):33-40. PubMed ID: 30318169
[TBL] [Abstract][Full Text] [Related]
12. Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma.
Blank CU; Rozeman EA; Fanchi LF; Sikorska K; van de Wiel B; Kvistborg P; Krijgsman O; van den Braber M; Philips D; Broeks A; van Thienen JV; Mallo HA; Adriaansz S; Ter Meulen S; Pronk LM; Grijpink-Ongering LG; Bruining A; Gittelman RM; Warren S; van Tinteren H; Peeper DS; Haanen JBAG; van Akkooi ACJ; Schumacher TN
Nat Med; 2018 Nov; 24(11):1655-1661. PubMed ID: 30297911
[TBL] [Abstract][Full Text] [Related]
13. Post-treatment changes in hematological parameters predict response to nivolumab monotherapy in non-small cell lung cancer patients.
Khunger M; Patil PD; Khunger A; Li M; Hu B; Rakshit S; Basu A; Pennell N; Stevenson JP; Elson P; Panchabhai TS; Velcheti V
PLoS One; 2018; 13(10):e0197743. PubMed ID: 30359383
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of Nivolumab and Pembrolizumab in Patients With Advanced Non-Small-Cell Lung Cancer Needing Treatment Interruption Because of Adverse Events: A Retrospective Multicenter Analysis.
Ksienski D; Wai ES; Croteau N; Fiorino L; Brooks E; Poonja Z; Fenton D; Geller G; Glick D; Lesperance M
Clin Lung Cancer; 2019 Jan; 20(1):e97-e106. PubMed ID: 30337270
[TBL] [Abstract][Full Text] [Related]
15. A case report of eyelid Merkel cell carcinoma occurring under treatment with nivolumab for a lung adenocarcinoma.
Lavacchi D; Nobili S; Brugia M; Paderi A; Fancelli S; Caliman E; Vergoni F; Mini E
BMC Cancer; 2018 Oct; 18(1):1024. PubMed ID: 30348121
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of anti-PD-1/PD-L1 antibodies after discontinuation due to adverse events in non-small cell lung cancer patients (HANSHIN 0316).
Tachihara M; Negoro S; Inoue T; Tamiya M; Akazawa Y; Uenami T; Urata Y; Hattori Y; Hata A; Katakami N; Yokota S
BMC Cancer; 2018 Oct; 18(1):946. PubMed ID: 30285770
[TBL] [Abstract][Full Text] [Related]
17. Clinical implications of monitoring nivolumab immunokinetics in non-small cell lung cancer patients.
Osa A; Uenami T; Koyama S; Fujimoto K; Okuzaki D; Takimoto T; Hirata H; Yano Y; Yokota S; Kinehara Y; Naito Y; Otsuka T; Kanazu M; Kuroyama M; Hamaguchi M; Koba T; Futami Y; Ishijima M; Suga Y; Akazawa Y; Machiyama H; Iwahori K; Takamatsu H; Nagatomo I; Takeda Y; Kida H; Akbay EA; Hammerman PS; Wong KK; Dranoff G; Mori M; Kijima T; Kumanogoh A
JCI Insight; 2018 Oct; 3(19):. PubMed ID: 30282824
[TBL] [Abstract][Full Text] [Related]
18. Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200): an open-label, randomised, phase 3 study.
Barlesi F; Vansteenkiste J; Spigel D; Ishii H; Garassino M; de Marinis F; Özgüroğlu M; Szczesna A; Polychronis A; Uslu R; Krzakowski M; Lee JS; Calabrò L; Arén Frontera O; Ellers-Lenz B; Bajars M; Ruisi M; Park K
Lancet Oncol; 2018 Nov; 19(11):1468-1479. PubMed ID: 30262187
[TBL] [Abstract][Full Text] [Related]
19. Health-related quality of life in cancer patients treated with PD-(L)1 inhibitors: a systematic review.
Abdel-Rahman O; Oweira H; Giryes A
Expert Rev Anticancer Ther; 2018 Dec; 18(12):1231-1239. PubMed ID: 30253680
[TBL] [Abstract][Full Text] [Related]
20. Pleural or pericardial metastasis: A significant factor affecting efficacy and adverse events in lung cancer patients treated with PD-1/PD-L1 inhibitors.
Kang DH; Chung C; Kim JO; Jung SS; Park HS; Park DI; Jung SY; Park M; Lee JE
Thorac Cancer; 2018 Nov; 9(11):1500-1508. PubMed ID: 30253080
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
